Related Experiment Video
Updated: Nov 4, 2025

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
MicroRNA-1253 Suppresses Cell Proliferation Migration and Invasion of Osteosarcoma by Targeting MMP9
Jianwen Mo1, Tiansheng Zheng1, Li Lei2
1Department of Orthopedic Surgery, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China.
Purpose:
MicroRNAs play an important role in osteosarcoma (OS) development and progress. Although miR-1253 was considered as a tumor-inhibitor in some cancers, it's function in the OS is not clear.
Methods:
In our study, we examined the expression of miR-1253 in OS cells and osteoblast cells using quantitative real-time PCR. The proliferation of OS cells was measured by BrdU assay, and we performed transwell to detect migration and invasion of OS cells. Meanwhile, EMT proteins were tested by western blot. We used Bioinformatics to predict the target genes of miR-1253 and found out Matrix metalloproteinases9 (MMP9) was one of that. The direct combination between miR-1253 and MMP9 was verified by double luciferase reporting experiment. Quantitative real-time PCR and western blot were used to detect the expression of MMP9.
Results:
We found that the expression level of miR-1253 in OS cells was significantly lower than that in osteoblast cells. Overexpression of miR-1253 could significantly inhibit OS cell proliferation, migration, invasion and EMT. And then, MMP9 was predicted as a downstream target of miR-1253 by Bioinformatics analysis. Further experiments showed that miR-1253 could reduce the protein level of MMP9 by directly binding to the 3'-UTR of MMP9. Afterward, we performed a rescue experiment, in which both MMP9 and miR-1253 were overexpressed. Compared with the groups overexpressed miR-1253 alone, cell proliferation, migration and invasion in co-overexpression groups were improved.
Conclusions:
In summary, these results suggested that miR-1253 down-regulated in OS cells, and could suppress the proliferation, migration and invasion of OS cells. Its molecular regulatory mechanism was that inhibits the expression of the downstream target gene MMP9 by directly binding, thus affect OS cell functions. Therefore, miR-1253 has the potential to become a biomarker and therapeutic target for OS therapy.
Insights
MicroRNA 1253 (miR-1253) is downregulated in osteosarcoma (OS) and inhibits cancer cell proliferation, migration, and invasion by targeting Matrix metalloproteinases 9 (MMP9). This suggests miR-1253 is a potential therapeutic target for OS.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- MicroRNAs (miRNAs) are crucial regulators in cancer development.
- The role of miR-1253 in osteosarcoma (OS) progression remains unclear, despite its tumor-inhibitory function in other cancers.
Purpose of the Study:
- To investigate the expression and function of miR-1253 in osteosarcoma.
- To elucidate the molecular mechanism underlying miR-1253's role in OS, including its potential targets.
Main Methods:
- Quantitative real-time PCR to assess miR-1253 and MMP9 expression.
- BrdU assay for cell proliferation, Transwell assays for migration and invasion.
- Western blot for EMT proteins and MMP9.
- Bioinformatics and dual-luciferase reporter assays to confirm miR-1253 targeting of MMP9.
Main Results:
- miR-1253 expression was significantly lower in OS cells compared to osteoblast cells.
- Overexpression of miR-1253 suppressed OS cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT).
- miR-1253 directly targets Matrix metalloproteinases 9 (MMP9), reducing its protein levels.
Conclusions:
- miR-1253 acts as a tumor suppressor in osteosarcoma by inhibiting proliferation, migration, and invasion.
- The mechanism involves direct downregulation of MMP9 expression.
- miR-1253 holds potential as a diagnostic biomarker and therapeutic target for osteosarcoma.
Related Concept Videos
MicroRNAs
MicroRNAs
Experimental RNAi
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

